The graft versus host disease (GVHD) market refers to the global market for therapies used to treat GVHD, a complication that can occur after stem cell or bone marrow transplant in which the transplanted immune cells (graft) attack the recipient’s body (host).
The GVHD market is driven by several factors, including the increasing prevalence of GVHD due to the rising number of bone marrow and stem cell transplants, increasing investments in research and development for GVHD therapies, and emerging therapies and advancements in GVHD treatment.
The market is segmented by type, treatment, end user, and geography. Types of GVHD include acute GVHD and chronic GVHD. Treatments for GVHD include corticosteroids, immunosuppressive agents, and monoclonal antibodies. End users of GVHD therapies include hospitals, clinics, and ambulatory surgical centers.
The global graft versus host disease market was valued at $3.0 billion in 2021, and is projected to reach $10.4 billion by 2031, growing at a CAGR of 13.5% from 2022 to 2031.
Graft versus host disease is a condition that occurs when donated stem cells or bone marrow (the graft) see the healthy tissues in the patient’s body (the host) as foreign and attack them. It can also occur after an organ transplant. It can cause damage to the host’s tissues and organs, especially the skin, liver, intestines, eyes, mouth, hair, nails, joints, muscles, lungs, kidneys, and genitals. The signs and symptoms may be severe and life threatening. It can occur within the first few months after transplant (acute) or much later (chronic).
Prime determinants of growth-
Surge in geriatric population and increase in the prevalence of nephrological, leukemia, myeloma, and lymphoma cancer drive the global graft versus host disease market. Furthermore, rise in number of bone marrow transplants being carried around the globe to treat specific types of cancers has supplemented the growth even more. Simultaneously, rise in the GVHD-prevalent population, advancements in the diagnostic measures of the disease, approval of novel treatments, and a greater range of prophylaxis options are expected to create lucrative opportunities in the industry.
Grab the Sample Report- https://www.alliedmarketresearch.com/request-sample/12294
Covid-19 scenario-
A sharp decline in the number of transplantation procedures.
The fact that it requires the routine use of reusable equipment with close contact with patients impacted the global graft versus host disease market negatively, especially during the initial period.
However, the market has already gotten back on track.
Get detailed COVID-19 impact analysis on the Graft Versus Host Disease Market- https://www.alliedmarketresearch.com/request-for-customization/12294?reqfor=covid
Key players in the industry-
Sanofi, Novartis AG, Merck & Co., Abbvie Inc, Pfizer Inc., Accord Healthcare Limited, Bristol Myer Squibb, Asahi Kasei Corporation, Glaxosmithkline plc, Incyte Corporation
The Acute GVHD segment to dominate by 2031-
By treatment type, the acute GVHD segment contributed to nearly three-fifths of the global graft versus host disease market share in 2021, and is expected to lead the trail by 2031. The same segment is also expected to exhibit the fastest CAGR of 5.8% from 2022 to 2031. Rise in the geriatric population coupled with increase in number of allogeneic transplantations drive the segment growth.
The hospitals pharmacies segment to maintain the lion’s share-
By end-use, the hospitals pharmacies segment accounted for more than two-fifths of the global graft versus host disease market revenue in 2021, and will dominate by 2031, due to surge in demand for transplantation drugs. At the same time, the online pharmacies segment would manifest the fastest CAGR of 14.0% during the forecast period, owing to the Covid-19 pandemic in which the buying pattern of most of the individuals has changed to online pharmacies.
For Purchase Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/12294
North America garnered the major share in 2021-
By region, North America garnered the major share in 2021, holding more than two-fifths of the global graft versus host disease market. This is attributed to increase in the number of organ donations of deceased persons for transplantation, rise in allogenic transplantation procedure, and surge in cancer patients in this province. Simultaneously, Asia-Pacific would cite the fastest CAGR of 15.9% throughout the forecast period, due to increase in demand for drugs such as corticosteroids and monoclonal antibodies across the region.
KEY FINDINGS OF THE STUDY
By product, the immunosuppressants segment was the highest contributor to the graft versus host disease market trend in 2021.
By type, the acute GVHD was the highest contributor to the graft versus host disease industry in 2021.
By end use, the online pharmacies segment is projected to grow at a significant CAGR of 14.0% from 2022 to 2031.
By region, North America garnered largest revenue share in 2021, whereas LAMEA is anticipated to grow at the highest CAGR of 15.9% during the review period.
FREQUENTLY ASKED QUESTIONS?
Q1. What are the upcoming trends of Graft Versus Host Disease Market in the world?
Q2. Which is the largest regional market for Graft Versus Host Disease?
Q3. What is the estimated industry size of Graft Versus Host Disease?
Q4. Which are the top companies to hold the market share in Graft Versus Host Disease?
Q5. Which factors might impact the Graft Versus Host Disease market negatively?
Other Top Trending Reports:
Care Management solutions market: https://www.alliedmarketresearch.com/care-management-solutions-market-A11913
Cell Cryopreservation Market: https://www.alliedmarketresearch.com/cell-cryopreservation-market-A11917
Contact:
David Correa
5933 NE Win Sivers Drive#205,
Portland, OR 97220
United States
USA/Canada (Toll Free): 1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.